MRC Environmental Epidemiology Unit, Community Clinical Sciences, University of Southampton, UK Correspondence to: Dr K T Palmer, MRC Environmental Epidemiology Unit, Southampton General Hospital, ...

Correspondence to Alberto Martini, University of Genoa, Pediatria II, Istituto G Gaslini, Largo Gaslini 5, Genova 16147, Italy; albertomartini{at}ospedale-gaslini.ge.it Juvenile idiopathic arthritis ...

The development of articular manifestations in the course of chronic urticaria or in urticarial vasculitis has been widely reported. It is not completely clear, however, whether common pathogenetic ...

1 Division of Clinical Immunology and Rheumatology, Academic Medical Centre/University of Amsterdam, The Netherlands 2 Department of Clinical Epidemiology and Biostatistics, Academic Medical ...

Department of Immunology and Transfusion Medicine, Ullevaal University Hospital, Oslo, Norway Correspondence to: Dr J Kjeldsen-Kragh, Department of Immunology and Transfusion Medicine, Ullevaal ...

1 Johns Hopkins University School of Medicine, Baltimore, Maryland, USA 2 University of Maryland, Baltimore, Maryland, USA Correspondence to Dr Michelle Petri, Professor of Medicine, Johns Hopkins ...

Objective: To compare the clinical efficacy of methotrexate and tolerance to the drug in patients with rheumatoid arthritis who were switched from intramuscular to oral administration because of a ...

Objective To assess the efficacy and safety of the type I interferon receptor antibody, anifrolumab, in patients with active, biopsy-proven, Class III/IV lupus nephritis. Methods This phase II ...

Correspondence to Dr Dimitrios T Boumpas, Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, "Attikon" University Hospital, Joint Academic Rheumatology Program, National ...

Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...

Study of the genetics of rheumatoid arthritis (RA) began about four decades ago with the discovery of HLA-DRB1. Since the beginning of this century, a number of non-HLA risk loci have been identified ...

Objective: To investigate whether determination of a set of laboratory markers at baseline provides prognostic information on joint damage in hands and feet in rheumatoid arthritis. Methods: 183 ...